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Background. In this study we retrospectively evaluated if 18F-FDG-PET/CT provided incremental diagnostic information over CI
in a group of hepatoblastoma patients performing restaging. Procedure. Nine patients (mean age: 5.9 years; range: 3.1–12 years)
surgically treated for hepatoblastoma were followed up by clinical examination, serum 𝛼-FP monitoring, and US. CI (CT or
MRI) and PET/CT were performed in case of suspicion of relapse. Fine-needle aspiration biopsies (FNAB) were carried out
for final confirmation if the results of CI, PET/CT, and/or 𝛼-FP levels were suggestive of relapse. PET/CT and CI findings were
analyzed for comparison purposes, using FNAB as reference standard. Results. 𝛼-FP level was suggestive of disease recurrence in
8/9 patients. Biopsy was performed in 8/9 cases. CI and PET/CT resulted to be concordant in 5/9 patients (CI identified recurrence
of disease, but 18F-FDG-PET/CT provided a better definition of disease extent); in 4/9 cases, CI diagnostic information resulted
in negative findings, whereas PET/CT correctly detected recurrence of disease. 18F-FDG-PET/CT showed an agreement of 100%
(8/8) with FNAB results.Conclusions. 18F-FDG-PET/CT scan seems to better assess HB patients with respect to CI andmay provide
incremental diagnostic value in the restaging of this group of patients.
1. Introduction
Primary liver tumors in pediatric patients represent a hetero-
geneous group of neoplasms with about 60% of malignant
forms. Hepatoblastoma (HB) is the most common primary
malignant hepatic tumor in childhood [1, 2]. Elevation of
serumalpha-fetoprotein (𝛼-FP) is seen in almost 90%of cases
[3, 4]. At present, complete resection is possible in more
than 50% of cases, and preoperative chemotherapy has been
successfully used in converting unresectable to resectable
tumors [5–7]. Followup bymeans of correlation of serial𝛼-FP
measurements and abdominal sonography (US), performed
2 BioMed Research International
every 3months for the first 2 year, may be helpful in detecting
relapse [8].
In the follow-up period, a rising level of serum 𝛼-
FP is generally associated with tumor recurrence; how-
ever, most protocols require additional imaging follow up,
since a neoplastic mass needs to be localized by US or
CT [9–11]. However, a negative imaging investigation does
not exclude the presence of recurrent disease [12] and
only biopsy can confirm it [3, 8, 13]. To our knowledge,
there are a few reports in the literature investigating the
role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission
tomography/computed tomography (18F-FDG-PET/CT) in
children with hepatoblastoma. In this retrospective study, we
evaluated if 18F-FDG-PET/CT provided incremental diag-
nostic information over conventional imaging (CI) in a group
of 9 hepatoblastoma patients undergoing restaging/followup
after surgery.
2. Methods
Nine patients (mean age: 5.9 years; range: 3.1–12 years) in
followup with a history of hepatoblastoma were retrospec-
tively evaluated. All patients were staged using the SIOPEL
staging system [18] and received chemotherapy according to
the SIOPEL protocol [19]: 4 cycles of PLADO (cisplatin plus
doxorubicin) and 2 cycles after transplantation (entire liver in
2/9 patients; left lateral segment from cadaveric donor in 4/9)
or surgery (in 3/9 cases). At the end of treatment, all patients
weremonitored by serial US andmeasurements of𝛼-FP level,
every three months for a median follow-up of 24 months.
In all patients, further investigations, including CI (CT or
MRI) and PET/CT, were requested within 1 week in case of
increase of 𝛼-FP serum level or clinical suspicion of relapse.
18F-FDG-PET/CT was performed in case of biochemical
relapse or findings on CI consistent with recurrence to better
evaluate the possible presence of additional lesions. 18F-FDG-
PET/CT was also asked by the pediatric oncologist, after
negative or inconclusive CI and 𝛼-FP results, if the suspicion
of recurrence was still high on the basis of the clinical
examination. Maximum time interval between CI (CT or
MRI) and PET/CT was 1 month. Fine-needle aspiration
biopsy (FNAB) was carried out for final confirmation if the
results of imaging studies and/or 𝛼-FP levels were suggestive
of relapse and used as reference standard to compare the
imaging results (PET/CT versus CI).
2.1. PET/CT Technique. The whole-body PET/CT scan was
done under fasting condition, 60 minutes after i.v. injection
of a fixed dose of 114MBq using integrated PET/CT device
(Discovery ST-E, General Electric Medical Systems, Milwau-
kee,WI, USA), scanning from the skull base to themid thigh,
with 5-6 fields of view (15 cm). Firstly, low-dose protocol CT
was performed with the purpose of attenuation correction
and anatomical localization of PET signal. CT images were
acquired on matrix of 512 × 512 pixels (pixel size = 1mm),
with a tube voltage of 80 kVp, pitch of helical of 3.75 : 1.
Maximum CT tube current was 20mAs, varying on the basis
of patient weight. No intravenous contrast agent was injected.
After CT, PET data were acquired in 3D mode on a matrix of
128 × 128 pixels.
2.2. Interpretation of PET/CT Imaging. PET/CT studies were
interpreted by means of visual and semiquantitative analysis
by means of Xeleris software (General Electric Medical
Systems) on the reconstructed attenuation corrected PET
and CT images in transaxial, coronal, and sagittal views by
two experienced nuclear medicine physicians. Semiquantita-
tive measurements of the tracer uptake using standardized
uptake value (SUVmax) were obtained by measuring the
ratio of the decay-corrected tracer uptake per gram of
tumor to the injected dose, normalized for body weight.
The SUVmax values were calculated in the largest tumor
deposits tominimize partial volume effects, using the average
pixel value within the region of interest. Furthermore, we
correlated 18F-FDG-PET/CT with biological and radiologi-
cal results and verified the possible presence of additional
findings.
3. Results
On the basis of FNAB and followup, there were 8 hepa-
toblastoma relapses and 1 disease-free patient. 𝛼-FP serum
levels were suggestive of recurrence of disease in 8 out of 9
patients at postsurgical followup. Biopsy was performed in
7/8 patients with increased 𝛼-FP level revealing positivity in
6/7 cases (results are summarized in Table 1).
A patient (no. 5, embryonal histotype) showed only
mildly raised 𝛼-FP level but negative CI and PET/CT imag-
ing. As a consequence FNABwas omitted, and the patient did
not show recurrence at the followup. In patient no. 2, neither
𝛼-FP level measurement nor CI was valuable in detecting
recurrence, which was depicted only by PET/CT (suggested
by the pediatric oncologist due to clinical suspicion) and
confirmed by biopsy.
CI and PET/CT resulted to be concordant in 5/9 patients;
however, in 4 of them, PET/CT provided a better definition of
disease extension; in one case both CI and PET/CT correctly
classified the patient as negative. In 4 cases (no. 2, no. 6, no.
7, and no. 9) with negative findings on CI, PET/CT correctly
detected recurrence of disease.
18F-FDG-PET/CT showed an agreement of 100% (8/8)
with FNAB results, while CI results were concordant with
FNAB results in 4/8 patients (case nos. 1, 3, 4, and 8).
Overall, 18F-FDG-PET/CT provided a better diagnostic per-
formance with respect to CI in the entire group of patients
and a more accurate definition of the extent of disease in
patients presenting recurrence. In one patient, CI correctly
detected hepatic recurrence butmissed additional abdominal
findings, which were showed on 18F-FDG-PET/CT scan. In
another case, CI correctly restaged hepatoblastoma (hepatic
recurrence and pulmonary metastases), whereas 18F-FDG-
PET/CT showed additional bilateral lung lesions. In patient
no. 4, CI correctly detected local recurrence in the liver,
but PET/CT depicted a higher number of lesions, while in
patient no. 8, CI was suggestive of recurrence, but PET/CT
documented an additional perisplenic lesion.
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Table 1: Characteristics of patients.
Patient
number Surgery 𝛼-FP increase Biopsy Recurrence CI findings
18F-FDG-PET/CT findings
1 Tx Yes Done Yes Hepatic recurrence Additional abdominal findings
2 Tx No Done Yes Negative Hepatic recurrence
3 Tx Yes Done Yes Hepatic recurrence and lung metastases Additional lung lesions
4 Tx Yes Done Yes Hepatic recurrence Additional hepatic lesions
5 Sx Yes Not done No Negative Negative
6 Sx Yes Done Yes Negative Epigastric lesion
7 Tx Yes Done Yes Negative Diaphragmatic lesion
8 Sx Yes Done Yes Perisplenic lesion Additional perisplenic lesion
9 Tx Yes Done Yes Negative Abdominal wall lesions
CI: conventional imaging; Tx: liver transplantation; Sx: hepatectomy.
4. Discussion
US is a noninvasive imaging method for the followup of
young patients affected by hepatoblastoma. However, US
provides less anatomic detail than CT and is less accurate in
the detection of hepatic tumors [20]. In addition, US may
not be as sensitive in the evaluation of the postoperative
bed due to the presence of either omental flap or gas-
filled loops of bowel [1]. CT is currently the modality
of choice to diagnose, evaluate preoperatively, and follow
up liver tumors in children [21]. Postoperative changes in
the liver are common and often do not reflect recurrent
or residual tumor: after liver resection, large mattress-type
sutures are usually placed into the remaining liver at the
resectionmargin; these can cause necrosis of adjacent hepatic
tissue, which may result in postoperative CT findings of low
attenuation and calcification. Moreover, changes in the liver
remote from resection margins may be due to intraoperative
trauma. Changes in attenuation on CT scan are found also
after chemotherapy and do not correlate well with tumor
necrosis on pathologic analysis [9]. Actually, MRI, which
usually requires sedation in children, is reserved mostly to
document a recurrent tumor and for instances of allergy to
iodine [1].
18F-FDG PET/CT is a recent nuclear medicine technique
that merges functional with anatomic imaging to optimize
disease assessment and evaluation of response to therapy.
18F-FDG uptake in tumors is proportional to the metabolic
rate of viable tumor cells, which have an increased demand
for glucose than normal tissue. Observations with electron
microscopy of ultrastructural characteristics of hepatoblas-
toma cells have demonstrated prominent glycogen granules
in the cytoplasm [22, 23]. The presence of copious glycogen
in hepatoblastoma cells suggests active accumulation of
glucose and its transformation and accumulation in glycogen
granules [24]. This observation can explain the uptake of
18F-FDG. 18F-FDG PET/CT has no established role in initial
diagnosis of hepatoblastoma [25] but is helpful in detecting
early recurrence [26], and few studies have evaluated its role
in followup and restaging of patients after chemotherapy and
surgery ([12, 14–17], Table 2).
Figarola et al. [12] documented a case in which a sus-
picion of hepatoblastoma recurrence after completion of
chemotherapy was confirmed by 18F-FDG-PET/CT which
correctly identified three pathological nodules in the liver,
whereas CT alone missed the anatomical detection. Philip
and colleagues, instead, reported in their article about three
hepatoblastoma patients; in one case, rising 𝛼-FP levels and
the failure to detect recurrent disease by CI led to the use
of FDG-PET. The PET study confirmed local recurrence,
leading to prompt surgical intervention that may have been
delayed otherwise [16]. Another manuscript describes the
use of FDG-PET in a series of 7 children (11 scans) with
primary hepatic malignancies (5 patients with hepatoblas-
toma and 2 patients with hepatic embryonal rhabdomyosar-
coma), together with other imaging (CT and MRI), serum
tumor markers, and tumor pathology. Abnormal uptake was
demonstrated in 6 of 7 patients. In one patient, intense
uptake was due to necrotizing granulomas [17]. Another
important study is that of Wong et al. [15], who suggest
caution in the interpretation of PET studies due to the
risk of false positive results. In this retrospective article
including sixteen children, three posttreatment patients had
PET results suggestive of tumor recurrence. One of these
patients had normal 𝛼-FP level and suspected recurrence in
the caudate lobe. Radiologic-guided biopsy was performed
3 times, and there was no evidence of tumor. The other 2
patients underwent further liver resections because of mildly
raised 𝛼-FP levels. The histology results showed regenerative
liver tissue only in both patients with no hepatoblastoma
recurrence [15].
Our series is one of the biggest in the literature and
confirms the findings of previous papers. One of the most
important points of this paper was the correlation of PET/CT
and CI results with biopsy. PET/CT showed a higher detec-
tion rate than CI (100% versus 44%), and we proved that
the technique could provide an additional means of evalu-
ating hepatoblastoma patients after surgical approach (liver
transplantation or hepatectomy) in the detecting sites of
recurrence (Figure 1).
In fact, PET imaging demonstrated more extensive
disease involvement than that revealed by other imaging
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Table 2: Characteristics of all studies reporting patients with hepatoblastoma evaluated by PET or PET/CT.
Authors Year Journal Country Study design
Number
of
patients
Device used Sex ofpatients
Mean age
(years) Indication
Sironi et al.
[14] 2004
American Journal
of Roentgenology Italy Case report 1 PET/CT 1M 4
Restaging
after Tx
Wong et al.
[15] 2004
Journal of
Pediatric Surgery Hong Kong Retrospective 16 PET 8M; 8 F 2
Restaging
after Sx
Figarola et al.
[12] 2005
Pediatric
Radiology USA Case report 1 PET/CT 1M 3
Restaging
after Sx
Philip et al.
[16] 2005
Pediatric Surgery
International Australia Case series 3
Coregistered
PET and CT NR 3
Restaging
after Sx
Mody et al.
[17] 2006
Pediatric Blood
and Cancer USA Prospective 5 PET 3M; 2 F 2
Restaging
after Sx;
response
evaluation
after Ch
M: male; F: female; Tx: liver transplantation; Sx: surgery; Ch: chemotherapy.
Figure 1: Peritoneal recurrence of hepatoblastoma. 18F-FDG-
PET/CT transverse images show a peritoneal nodular mass with
abnormal FDGuptake suspicious for recurrent hepatoblastoma.The
biopsy confirmed the diagnosis.
modalities in 7/9 patients. CI failed in detecting one hep-
atic recurrence and a considerable number of extrahepatic
lesions. Biomarker measurements registered a false positive
case (mild increase 𝛼-FP level with no disease recurrence
detection at both PET/CT and CI) and a false negative
result. These results can be explained since 𝛼-FP is not
always a reliable marker in infants with hepatoblastoma,
due to the physiologically elevated levels of 𝛼-FP in this
age group [27] or due to the lack of 𝛼-FP production
in undifferentiated tumors [28]. Despite this aspect, 𝛼-FP,
being a noninvasive and high-sensitive method in detecting
recurrence, is considered the gold standard in this setting
[29] and allows decreasing frequency of imaging surveillance
examinations and radiation exposure. Furthermore, in the
routine clinical practice many institutions use to perform at
least an additional measurement of 𝛼-FP level to minimize
risk of false positive.
Overall, our results enforce the role of 18F-FDG PET/CT
in the restaging of hepatoblastoma patients after chemother-
apy and surgery. From our point of view, although 18F-
FDG PET/CT has no definite role in the staging workup of
hepatoblastoma [24], it could provide incremental diagnostic
value in the initial evaluation of patients affected by hepa-
toblastoma, helping to detect additional metastatic sites at
diagnosis. However, since experience is so far limited in the
literature, multicentre and prospective studies are warranted
to validate the role of 18F-FDG PET/CT in this latter setting.
Potential limits of 18F-FDG-PET/CT are lesion dimensions,
because of PET maximal spatial resolution of 4mm. In
addition, possibility of false positive and false negative should
be taken into account. The minimal mitotic activity of the
pure fetal subtype may demonstrate lower FDG avidity than
other more unfavorable hepatoblastoma histotypes and lead
to false negative exam, thus limiting the effectiveness of 18F-
FDG-PET/CT in staging hepatoblastoma [30]. Besides, as
described for other tumors, an acute hyperglycaemia at the
time of the exam can compete with tracer uptake and lead to
false negative reports [17]. Conditions leading to false positive
18F-FDG-PET/CT examinations include regenerating liver
tissue and areas of inflammation (like necrotizing granulo-
mas) and should be reminded when 𝛼-FP levels are only
slightly or moderately elevated [15, 17].
Also, respiratory motion in children can be a problem
causing misregistration of PET and CT scans and leading to
attenuation correction artifacts, as in the case of a focal uptake
in the dome of the liver, which could be falsely localized to
the lung base on the attenuation-corrected images [31].These
pitfalls are due to the difference in diaphragm position at CT
and PET. Misregistration may be minimized by performing
CT during midexpiration [32–34]. Last but not least, radia-
tion doses provided by additional imaging investigations to
pediatric patients should be carefully evaluated as suggested
by former papers [35, 36]. The effective dose provided by
one PET/CT scan, according to our imaging protocol, ranges
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from 7.3 to 9.3mSv, whereas the effective dose for an infant
undergoing high quality abdominal CT is about 8–10mSv
(tube voltage = 120 kVp; tube current = 80mAs; abdominal
pitch of 1.5 : 1).
5. Conclusions
PET/CT is nowadays an emerging diagnostic tool, which
is acquiring an increasing importance in pediatrics. Our
experience suggests that 18F-FDG-PET/CT scan may be
used in children with HB without collateral effects and may
provide incremental diagnostic value over CI in restaging and
followup. Considering the importance of restaging disease
after surgical approach, we stress the importance of rapid
and correct disease extent definition in the event of recur-
rence. The association between morphological exams and
functional images acquired at the same moment seems to
be striking in the definition of disease extent. However, it is
important to carefully evaluate, case by case, the necessity of
performing PET/CT in hepatoblastoma in order to minimize
the radiation exposure in pediatric patients. As this pathology
is rare, more complex multicentre trials are warranted to
suggest the introduction of 18F-FDG-PET/CT in the routine
imaging workup for hepatoblastoma staging and in case of
suspicion of relapse.
Conflict of Interests
The authors declare that they have no conflict of interests.
References
[1] C. E. Herzog, R. J. Andrassy, and F. Eftekhari, “Childhood
cancers: hepatoblastoma,” Oncologist, vol. 5, no. 6, pp. 445–453,
2000.
[2] J. B. Litten and G. E. Tomlinson, “Liver tumors in children,”
Oncologist, vol. 13, no. 7, pp. 812–820, 2008.
[3] E. M. Chung, G. E. Lattin Jr., R. Cube et al., “From the archives
of the AFIP: pediatric liver masses: radiologic-pathologic cor-
relation part 2. malignant tumors,” Radiographics, vol. 31, no. 2,
pp. 483–507, 2011.
[4] J. J. Gregory Jr. and J. L. Finlay, “𝛼-fetoprotein and 𝛽-human
chorionic gonadotropin. Their clinical significance as tumour
markers,” Drugs, vol. 57, no. 4, pp. 463–467, 1999.
[5] J. Zs´ıros, R. Maibach, E. Shafford et al., “Successful treatment
of childhood high-risk hepatoblastoma with dose-intensive
multiagent chemotherapy and surgery: final results of the
SIOPEL-3HR study,” Journal of Clinical Oncology, vol. 28, no.
15, pp. 2584–2590, 2010.
[6] L. F. Avila, A. L. Luis, F. Hernandez et al., “Liver transplantation
for malignant tumours in children,” European Journal of Pedi-
atric Surgery, vol. 16, no. 6, pp. 411–414, 2006.
[7] M. Hertl and A. B. Cosimi, “Liver transplantation for malig-
nancy,” Oncologist, vol. 10, no. 4, pp. 269–281, 2005.
[8] B. Parikh, A. Jojo, B. Shah, R. Bansal, P. Trivedi, and M. J. Shah,
“Fine needle aspiration cytology of hepatoblastoma: a study of
20 cases,” Indian Journal of Pathology and Microbiology, vol. 48,
no. 3, pp. 331–336, 2005.
[9] S. J. King, P. S. Babyn, M. L. Greenberg, M. J. Phillips, and
R. M. Filler, “Value of CT in determining the resectability
of hepatoblastoma before and after chemotherapy,” American
Journal of Roentgenology, vol. 160, no. 4, pp. 793–798, 1993.
[10] D. Iacob, A. Serban, O. Fufezan et al., “Mixed hepatoblastoma
in child. Case report,”Medical ultrasonography, vol. 12, no. 2, pp.
157–162, 2010.
[11] G. Perilongo, E. Shafford, and J. Plaschkes, “SIOPEL trials
using preoperative chemotherapy in hepatoblastoma,” Lancet
Oncology, vol. 1, no. 2, pp. 94–100, 2000.
[12] M. S. Figarola, S. A. McQuiston, F. Wilson, and R. Powell,
“Recurrent hepatoblastoma with localization by PET-CT,” Pedi-
atric Radiology, vol. 35, no. 12, pp. 1254–1258, 2005.
[13] L. Abbasogˇlu, F. Gu¨n, F. Tansu Salman et al., “Hepatoblastoma
in children,”Acta Chirurgica Belgica, vol. 104, no. 3, pp. 318–321,
2004.
[14] S. Sironi, C.Messa, A. Cistaro et al., “Recurrent hepatoblastoma
in orthotopic transplanted liver: detection with FDG positron
emission tomography,” American Journal of Roentgenology, vol.
182, no. 5, pp. 1214–1216, 2004.
[15] K. K. Y. Wong, L. C. L. Lan, S. C. L. Lin, and P. K. H. Tam,
“The use of positron emission tomography in detecting hepa-
toblastoma recurrence—a cautionary tale,” Journal of Pediatric
Surgery, vol. 39, no. 12, pp. 1779–1781, 2004.
[16] I. Philip, A. Shun, G. McCowage, and R. Howman-Giles,
“Positron emission tomography in recurrent hepatoblastoma,”
Pediatric Surgery International, vol. 21, no. 5, pp. 341–345, 2005.
[17] R. J.Mody, J. A. Pohlen, S.Malde, P. J. Strouse, and B. L. Shulkin,
“FDG PET for the study of primary hepatic malignancies in
children,” Pediatric Blood and Cancer, vol. 47, no. 1, pp. 51–55,
2006.
[18] D. C. Aronson, J. M. Schnater, C. R. Staalman et al., “Predictive
value of the pretreatment extent of disease system in hepato-
blastoma: results from the International Society of Pediatric
Oncology Liver Tumor Study Group SIOPEL-1 study,” Journal
of Clinical Oncology, vol. 23, no. 6, pp. 1245–1252, 2005.
[19] J. Pritchard, J. Brown, E. Shafford et al., “Cisplatin, doxoru-
bicin, and delayed surgery for childhood hepatoblastoma: a
successful approach—results of the first prospective study of the
International Society of Pediatric Oncology,” Journal of Clinical
Oncology, vol. 18, no. 22, pp. 3819–3828, 2000.
[20] P. O. Alderson, D. F. Adams, and B. J. McNeil, “Computed
tomography, ultrasound, and scintigraphy of the liver in
patients with colon or breast carcinoma: a prospective compar-
ison,” Radiology, vol. 149, no. 1, pp. 225–230, 1983.
[21] M. A. Amendola, C. E. Blane, B. E. Amendola, andG.M.Glazer,
“CT findings in hepatoblastoma,” Journal of Computer Assisted
Tomography, vol. 8, no. 6, pp. 1105–1109, 1984.
[22] A.Horie, Y. Kotoo, andT.Hayashi, “Ultrastructural comparison
of hepatoblastoma and hepatocellular carcinoma,” Cancer, vol.
44, no. 6, pp. 2184–2193, 1979.
[23] K. A. Warfel and M. T. Hull, “Hepatoblastomas: an ultra-
structural and immunohistochemical study,” Ultrastructural
Pathology, vol. 16, no. 4, pp. 451–461, 1992.
[24] N. Shiojiri, “Enzymo- and immunocytochemical analyses of the
differentiation of liver cells in the prenatal mouse,” Journal of
Embryology and Experimental Morphology, vol. 62, pp. 139–152,
1981.
[25] C. D. Patel and R. Kumar, “Positron emission tomography and
positron emission tomography-computerized tomography in
pediatric patients,” Journal of Indian Association of Pediatric
Surgeons, vol. 12, no. 3, pp. 120–124, 2007.
6 BioMed Research International
[26] W. T. Yang and P. J. Johnson, “Monitoring response to treatment
in liver tumours,”Bailliere’s Best Practice andResearch inClinical
Gastroenterology, vol. 13, no. 4, pp. 637–654, 1999.
[27] F. Bertagna, E. Orlando, G. Bosio et al., “Incremental diagnostic
value of F-18 FDG PET/CT over MRI in a pediatric patient
with suspected hepatoblastoma and histologic diagnosis of focal
nodular hyperplasia,” Clinical nuclear medicine, vol. 36, no. 4,
pp. 305–308, 2011.
[28] E. J. Groen, A. Roos, F. L. Muntinghe et al., “Extra-intestinal
manifestations of familial adenomatous polyposis,” Annals of
Surgical Oncology, vol. 15, no. 9, pp. 2439–2450, 2008.
[29] G. Perilongo and E. A. Shafford, “Liver tumours,” European
Journal of Cancer, vol. 35, no. 6, pp. 953–959, 1999.
[30] M. B. McCarville and D. J. Roebuck, “Diagnosis and staging
of hepatoblastoma: imaging aspects,” Pediatric Blood & Cancer,
vol. 9, no. 5, pp. 793–799, 2012.
[31] F. A. Falix, D. C. Aronson, W. H. Lamers et al., “DLK1, a serum
marker for hepatoblastoma in young infants,” Pediatric Blood &
Cancer, vol. 59, pp. 743–745, 2012.
[32] A. Shammas, R. Lim, andM.Charron, “Pediatric FDGPET/CT:
physiologic uptake, normal variants, and benign conditions,”
Radiographics, vol. 29, no. 5, pp. 1467–1486, 2009.
[33] J. P. Finn, M. A. HaIl-Craggs, C. Dicks-Mireaux et al., “Primary
malignant liver tumors in childhood: assessment of resectability
with high-field MR and comparison with CT,” Pediatric Radiol-
ogy, vol. 21, pp. 34–38, 1990.
[34] G. J. R. Cook, E. A. Wegner, and I. Fogelman, “Pitfalls and
artifacts in 18FDG PET and PET/CT oncologic imaging,”
Seminars in Nuclear Medicine, vol. 34, no. 2, pp. 122–133, 2004.
[35] W. Huda and A. Vance, “Patient radiation doses from adult and
pediatric CT,” American Journal of Roentgenology, vol. 188, no.
2, pp. 540–546, 2007.
[36] F.H. Fahey, “Dosimetry of pediatric PET/CT,” Journal ofNuclear
Medicine, vol. 50, no. 9, pp. 1483–1491, 2009.
